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Decreased arterial compliance in end-stage renal disease
(ESRD) is associated with increased cardiovascular risk. Our
aim was to examine aortic compliance in patients with ESRD
using cardiac magnetic resonance imaging (MRI) and to
compare these with patients with advanced atherosclerotic
disease who are known to be at high cardiovascular risk. We
examined a total of 83 subjects matched for age: 24 had
ESRD and were on dialysis therapy for 376 years, 24 had
severe coronary artery disease (CAD), 11 had both ESRD and
CAD (475 years on dialysis therapy), and 24 healthy subjects
with no evidence of CAD. Vascular and cardiac function
was assessed using cardiac MRI. Aortic compliance was
significantly reduced in patients with CAD compared
to control subjects (11.376.3 ml . 103/mm Hg vs
15.676.0 ml . 103/mm Hg, P¼ 0.009). Patients with ESRD
also exhibited significantly reduced aortic compliance
compared to healthy controls (12.475.8 ml . 103/mm Hg vs
15.676.0 ml 103/mm Hg, P¼ 0.012), whereas there was no
significant difference in aortic compliance between patients
with CAD and ESRD. Even in the absence of symptomatic
CAD, patients with ESRD have significantly reduced aortic
compliance compared to normal subjects. Patients with ESRD
have equivalent aortic compliance to patients with advanced
CAD. These findings suggest that a significantly reduced
aortic compliance is one of many mechanisms promoting
premature cardiovascular events in patients with ESRD
compared to age-matched controls from the general
population.
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Despite advances in renal replacement therapy, patients with
end-stage renal disease (ESRD) have a greatly increased risk
of premature cardiovascular morbidity and mortality.1
Although these patients frequently have a high burden of
traditional cardiovascular risk factors for coronary artery
disease (CAD) such as diabetes mellitus, smoking, hyper-
tension, and hyperlipidemia, the relationship between modifi-
able cardiovascular risk factors and long-term outcome is less
clear than in the general population. For example, there is a
U-shaped curve describing the interaction between both
blood pressure and cholesterol and mortality in patients with
ESRD.2 Epidemiological and clinical studies have shown that
increased arterial stiffness, most commonly assessed by measure-
ment of pulse wave velocity (PWV) or augmentation index, is
independently associated with cardiovascular morbidity and
mortality in these patients.3,4 However, although these
studies are robust, using applanation tonometry as an
indirect measure of central arterial function may be prone
to limitations.3
Cardiovascular magnetic resonance imaging (MRI) accu-
rately defines cardiac dimensions and is currently accepted as
the ‘gold standard’ for measurement of left ventricular (LV)
mass.5,6 In addition cardiac MRI permits visualization of
large arteries and blood flow. It thereby facilitates direct
measurement of aortic compliance and aortic PWV.7
Previous studies using cardiac MRI to assess PWV have
focused on normal volunteers to validate the technique.8
Given the strong relationship between vascular stiffness and
outcome in ESRD we used MRI to assess cardiac and vascular
function in this patient group. Furthermore, we compared
subjects with ESRD with patients with advanced athero-
sclerotic disease at high cardiovascular risk and healthy
controls.
RESULTS
Patient characteristics
Patient demographics and results from biochemical and
imaging studies are depicted in Tables 1 and 2. Control
subjects had lower blood pressure and C-reactive protein
levels compared to all of the patient groups. Patients with
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ESRD had higher C-reactive protein levels compared to
subjects in the other groups. Owing to treatment with statins
total cholesterol and low-density lipoprotein cholesterol
levels were lower in patients with CAD than in the other
groups. However, control subjects had higher high-density
lipoprotein cholesterol levels compared to other groups and
were more likely to be never-smokers compared to patients
with CAD.
Aortic compliance
Aortic compliance was significantly reduced in patients with
CAD compared to control patients (11.376. 3 ml  103/mm
Hg vs 15.676.0 ml  103/mm Hg, P¼ 0.009); Figure 1.
Patients with ESRD also exhibited significantly reduced
aortic compliance compared to healthy controls (12.47
5.8 ml  103/mm Hg vs 15.676.0 ml  103/mm Hg,
P¼ 0.012), whereas there was no significant difference in
aortic compliance between patients with CAD and ESRD
(P¼ 1.00). The group of patients with both conditions was
relatively small. However, their compliance tended to be
lower than in patients with ESRD only (9.376.0 ml  103/
mm Hg vs 12.475.8 ml  103/mm Hg, P¼ 0.15).
Table 1 | Baseline characteristics
Controls CAD ESRD ESRD+CAD
(n=24) (n=24) (n=24) (n=11) P-value
Age (y) 57710 57710 5679 55710 0.950
Sex (male/female) 13/11 17/7 12/12 10/1 0.078
Time on renal replacement therapy (y) — — 376 475 N/A
Body mass index (kg/m2) 26.472.9 29.275.7 25.173.7 26.475.4 0.017
Smokers, active/stopped/none 2/6/16 6/11/7 7/4/13 5/3/3 0.038
Diabetic (n) 0 4 3 5 0.002
Statin therapy (n) 1 22 6 7 o0.001
Systolic blood pressure (mm Hg) 122715 124714 135735 150724 0.001
Diastolic blood pressure (mm Hg) 76710 72711 79712 87712 0.005
Pulse pressure (mm Hg) 44 (29; 52) 48 (42; 52) 54 (40; 67) 65 (44; 84) 0.058
Total cholesterol (mmol/l) 5.571.3 4.270.8 4.870.9 4.871.1 0.001
LDL cholesterol (mmol/l) 3.371.2 2.170.6 2.971.0 2.870.8 0.001
HDL cholesterol (mmol/l) 1.570.5 1.170.4 0.970.2 1.170.3 0.001
Triglycerides (mmol/l) 1.2 (0.9; 2.0) 1.9 (1.1; 2.5) 1.9 (1.5; 2.4) 1.8 (1.4; 2.5) 0.066
C-reactive protein (mg/l) 1.4 (0.5; 2.7) 2.3 (1.1; 3.4) 5.6 (2.3; 12.0) 10.2 (2.8; 31.5) 0.001
Creatinine (mmol/l) 91710 101720 — — N/A
eGFR (ml/min/1.73m2) 73713 68716 — — N/A
CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; N/A, not
available; y, year.
P-values derive from one-way analysis of variance, Kruskal–Wallis test, w2-test or Fisher’s exact test as appropriate.
Table 2 | Vascular and cardiac structure and function measured with cardiac MRI
Controls CAD ESRD ESRD+CAD
(n=24) (n=24) (n=24) (n=11) P-value
Compliance (ml  103/mm Hg) 15.676.0 11.376.3 12.475.8 9.376.0 0.020
Pulse wave velocity (m/s) 7.471.9 7.671.9 8.572.2 8.573.3 0.407
Ejection fraction (%) 63.075.3 61.477.7 66.876.4 47.8712.8 o0.001
Left ventricular mass (g) 98.5727.0 111.2731.3 153.6759.2 208.6759.6 o0.001
Left ventricular mass index (g/m2) 52.6711.2 58.6711.9 82.0729.1 109.2731.7 o0.001
End-systolic volume (ml) 56.1717.6 61.4722.6 53.9724.8 118.3747.8 o0.001
End-systolic volume index (ml/m2) 30.178.7 32.6711.6 29.1712.6 61.6723.1 o0.001
End-diastolic volume (ml) 149.7735.0 155.3735.4 158.4755.8 221.9757.9 o0.001
End-diastolic volume index (ml/m2) 80.3715.9 82.7716.1 85.2727.6 115.6727.7 o0.001
CAD, coronary artery disease; ESRD, end-stage renal disease; MRI, magnetic resonance imaging.
P-values derive from one-way analysis of variance.
For pulse wave velocity the number of recordings was smaller (21/19/15/7 for controls/CAD/ESRD/ESRD+CAD, respectively).
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Figure 1 | Aortic compliance shown in control subjects, patients
with CAD, ESRD, and ESRDþCAD, respectively; one-way analysis
of variance F¼ 3.468, Po0.02.
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In the whole cohort, there was a highly significant
correlation between age and compliance; aortic compliance
declined with increasing age (r¼0.498, Po0.001). Multiple
stepwise linear regression analysis showed that age
(Po0.001), presence or absence of CAD (P¼ 0.001), and
presence or absence of ESRD (P¼ 0.010) determined aortic
compliance, whereas sex and mean arterial blood pressure
did not enter the model (adjusted R2¼ 0.349).
PWV
PWV was lowest in the control group (7.471.9 m/s)
compared to patients with CAD (7.671.9 m/s), ESRD
(8.572.2 m/s), and patients with both CAD and ESRD
(8.573.3 m/s). However, none of the comparisons between
groups reached the prespecified level of significance. In the
whole cohort, there was a highly significant correlation
between age and PWV; PWV increased with increasing age
(r¼ 0.414, P¼ 0.001). There was a significant correlation
between PWV and aortic compliance in the whole study
group (r¼0.470, Po0.001).
LV mass and function
There was no significant difference in LV mass index between
healthy subjects and CAD patients (58.6711.9 g/m2,
P¼ 0.09). LV mass index was significantly higher in patients
with ESRD compared to healthy subjects (82.0729.1 g/m2 vs
52.6711.2 gm2, Po0.001). In patients with CAD and ESRD,
LV mass index was higher than in patients with ESRD
(109.2731.7 g/m2 vs 82.0729.1 gm2, P¼ 0.048). LV ejection
fraction was similar between patients with CAD, patients
with ESRD and healthy controls (61.477.7, 66.876.4,
63.075.3%, respectively; all P¼ 1.00). Ejection fraction was
lower in patients with both ESRD and CAD compared to
patients with ESRD (47.8712.8 vs 66.876.4%, P¼ 0.002).
DISCUSSION
This study is to our knowledge the first report using cardiac
MRI to assess aortic compliance in patients with ESRD. Our
results demonstrate that even in the absence of significant
coronary artery atherosclerosis, patients with ESRD have
significantly reduced aortic compliance compared to normal
subjects and that these patients have equivalent aortic
compliance to patients with advanced CAD severe enough
to require surgical revascularization. In the small group of
subjects with ESRD and CAD, there was a trend towards a
further reduction in aortic compliance as compared with
patients with ESRD and no CAD. However, this group is too
small to draw firm conclusions.
First, these findings suggest that a significant increase in
arterial stiffness may be one of the many mechanisms
promoting cardiovascular events in patients with ESRD.
Second, even in the presence of ESRD, severe CAD is
associated with reduced aortic compliance implying that
impaired arterial function in these patients is a cumulative
result of two factors – large artery damage, specific to uremia
and further damage owing to atherosclerosis. We have also
demonstrated by cardiac MRI that patients with severe CAD
and normal renal function have a significant increase of
arterial stiffness compared to age-matched controls.
The mechanisms responsible for increased arterial stiffness
in ESRD are both complex and incompletely understood.
Arterial abnormalities in ESRD are heterogeneous and
associate atherosclerosis and remodelling with aging and
hemodynamic alterations.9 Major architectural abnormalities
are fibroelastic intimal thickening, calcification of elastic
lamellae, increased extracellular matrix with more collagen,
and relatively less elastic fiber content.10,11 Factors most
frequently quoted in association with increased arterial
stiffness in patients with ESRD are altered calcium and
phosphate metabolism and parathyroid activity.10 Arterial
calcification is a common complication in ESRD,10,12 and the
extent of arterial calcification is predictive of subsequent
cardiovascular mortality beyond established risk factors.13,14
Calcification occurs in two different parts of the vessel wall,
the media and the intima, and previous reports have
suggested that patients with intimal calcifications are older
and have a burden of traditional cardiovascular risk factors
such as smoking and dyslipidemia, whereas medial calcifica-
tion is seen in younger patients and may therefore be a
finding more unique to uremia.14 We were unable to
demonstrate any correlation between calcium, phosphate,
or time on dialysis and arterial stiffness, but in keeping with
other studies we did find that age was associated with a
significant reduction in arterial compliance (data not shown).
Together with age, other factors such as presence or absence
of atherosclerosis and/or renal disease seem to be important
predictors of aortic compliance.
The group of patients with normal renal function and
severe CAD represents the largest cohort of patients with
coronary atherosclerosis studied by cardiac MRI. We have
confirmed with this technique that CAD patients are
characterized by a significant reduction in arterial compliance
compared to age-matched controls. Additionally, as these
patients were treated with aggressive lipid lowering therapy, it
is not possible to draw any conclusions regarding serum
cholesterol or inflammatory markers, both being ameliorated
by statin therapy.15–17
Our study also highlights some limitations of this
technique. First, although it is highly likely that vascular
stiffness is the chief mechanism for reduced aortic compli-
ance, cardiac MRI is unable to display calcific lesions owing
to their absence of water (and hence proton) content. This
compares relatively unfavourably with multi-slice computed
tomography, which has emerged as a tool for assessing
cardiac calcification.18 However, multi-slice computed tomo-
graphy is not able to accurately distinguish between intimal
and medial calcification and requires ionizing radiation.
Therefore making serial scans to test a therapeutic interven-
tion a less attractive option, than using cardiac MRI surrogate
measures of calcification. Second, calculation of aortic
compliance is based on cross-sectional volume of the vessel
wall and pulse pressure. It should be noted that for practical
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reasons, direct aortic blood pressure measurement has been
substituted by non-invasive indirect brachial blood pressure
measurement.19–21 Another important limitation of our study
is the small number of patients with both conditions, ESRD
and CAD. This is mainly owing to the rigorous definition of
angiographically confirmed CAD. Comorbid cardiovascular
disease is prevalent in approximately 30% of dialysis patients
at initiation of therapy.22 However, this may be ill defined,
owing to poor correlation between symptoms, angiographic
findings, and outcome. We chose to define CAD angio-
graphically in patients with ESRD using similar criteria as in
the CAD group and this has limited our numbers. Non-invasive
tests for CAD have a high false-positive rate in this
population.23
In conclusion, a MRI scan offers a 25-min examination of
both vascular and cardiac function. Cardiac MRI is currently
widely used as a high fidelity research method for the
assessment of LV mass and function24 and is being
increasingly used in clinical practice.25 By assessing vascular
function in the same examination as an LV study, we have
demonstrated that it is possible to acquire important
additional data. We have shown significant abnormalities in
patients with a high burden of atherosclerotic disease and
with ESRD. Cardiac MRI measures of aortic compliance
may represent potential targets for therapeutic interventions
in patients with ESRD who are at a very high risk of
cardiovascular events.
MATERIALS AND METHODS
Subjects
We examined a total of 83 subjects. Group 1 consisted of 24 patients
with triple-vessel CAD confirmed by coronary angiography who
were about to undergo elective coronary artery bypass graft surgery
on the following day at the Department of Cardiothoracic Surgery,
Western Infirmary, Glasgow. Group 2 comprised 24 patients with
ESRD in whom CAD has been ruled out by coronary angiography or
exercise tolerance test. Group 3 consisted of 11 patients with ERSD
and CAD defined by stenosis X70% of at least one epicardial
coronary artery at coronary angiography. The renal patients were
recruited from the Renal Unit, Western Infirmary, Glasgow. Twenty-
four subjects with no history of angina, CAD, or peripheral artery
disease, who were recruited from a local health club and from
surgical wards at Gartnavel General Hospital, Glasgow, served as
controls. Blood samples were collected on the day of the MRI scan.
Plasma total cholesterol, low-density lipoproteins, high-density
lipoproteins, triglycerides, high-sensitivity C-reactive protein, and
serum creatinine were assessed using standard biochemical methods.
The Modification of Diet in Renal Disease formula was used for the
estimation of glomerular filtration rate in CAD patients and healthy
volunteers.26
All subjects in the four groups were matched for age (within
3 years). The study was approved by the West Glasgow Ethics
Committee and all subjects gave written informed consent.
Cardiac MRI technique
All study participants underwent cardiac MRI using a 1.5. Tesla MRI
scanner (Sonata, Siemens, Erlangen, Germany). MRI was performed
1 day before bypass graft surgery in the CAD patients. In patients on
hemodialysis imaging was performed on the post-dialysis day
whereas patients on peritoneal dialysis were studied at their ‘dry
weight’. Overall scan time was approximately 25 min.
To measure aortic compliance, cine MR images in the transverse
plane of the ascending aorta were obtained at the level of the main
pulmonary artery (Figure 2), utilizing true fast imaging with steady-
state precession (true FISP) sequence (repetition time 3.2 ms, echo
time 1.6 ms, flip angle 601, field of view 276 340 mm, pixel
dimensions 2.3 1.3 mm, slice thickness 7 mm). The approximately
10 s breath-hold MRI resulted in prospective images with a temporal
resolution of 22.5 ms. During compliance measurement, brachial
systolic and diastolic blood pressures were measured within the
scanner, using an MRI-compatible oscillometric device (Schiller
Magscreen monitoring system, Schiller AG, Baar, Switzerland).
Although aortic compliance was the primary focus of this study,
we measured PWV in a subset of patients (n¼ 62). A fast low angle
shot gradient-echo pulse sequence (repetition time 41 ms, echo time
3.2 ms, flip angle 301, field of view 192 256, pixel dimensions
1.5 1.5, slice thickness 5 mm) was applied perpendicular to the
aorta at two levels: at the level of the crossing of the pulmonary
artery through the ascending (in the same plane as the compliance
sequence) and descending aorta and at the level of the diaphragm
(Figure 3). This resulted in multiphase image pairs of modulus- and
velocity encoded images with a temporal resolution of approxi-
mately 20.7 ms throughout the cardiac cycle.
LV mass and function were measured using a true FISP sequence
to acquire cine images in long axis planes (vertical long axis,
horizontal long axis, and LV outflow tract) followed by sequential
short axis LV cine loops (8-mm slice thickness, 2 mm gap between
slices) from the atrioventricular ring to the apex. Imaging
parameters, which were standardized for all subjects, included the
following: repetition time 3.2 ms, echo time 1.6 ms, flip angle 201,
field of view 276 340 mm, pixel dimensions 2.3 1.3 mm, and
slice thickness 8 mm.
Image analysis and calculations
To calculate compliance, aortic volumes were measured by manual
tracing of the cross sectional area of the vessel lumen using analysis
software (Argus VA60C 2004, Siemens, Erlangen, Germany) which
was multiplied by the slice thickness (Figure 2). Aortic compliance
was calculated according to the following formula:
Compliance ¼ ½ðAortic volumeÞmax  ðAortic volumeÞmin	=DP
AAo
DAo
Figure 2 | Ascending aorta (AAo) and descending aorta (DAo)
shown in cross section, with ascending aortic contour traced for
compliance measurement.
Kidney International (2007) 71, 68–73 71
LU Zimmerli et al.: Vascular function in end-stage renal disease o r i g i n a l a r t i c l e
where (Aortic volume)max and (Aortic volume)min are the maximal
and minimal calculated aortic volumes obtained during the cardiac
cycle, respectively, and DP is the pulse pressure.
PWV was computed based on the upstroke difference of the
velocity time curves at two different regions:
PWV ¼ Dx=Dt;
where Dx is the length, and Dt is the time difference of initial flow
acceleration between two regions of interest. To calculate distances
between levels, views of the complete aortic arch were loaded into an
off-line analysis programme (Cardiowarp, in-house software). A
skeletonization algorithm was applied to the aorta shape in order to
extract a midline of the section of interest (Figure 3a). The upstroke
flow curves were normalized to their own maximum value using
off-line analysis software (Origin 6.1, OriginLab Corporation,
Northampton, MA, USA). In the region between 0.2 and 0.5 the
curves were consistently linear and parallel and therefore the time
delay could be computed directly (Figure 3b).8
LV function and mass were analyzed as previously described in
detail.27 In brief, from short axis cine loops LV epicardial and
endocardial contours were manually traced in end systole and end
diastole and LV mass and ejection fraction calculated using analysis
software.
Statistical analysis
All of the statistical analyses were performed using SPSS software
package (SPSS for Windows 12.0, SPSS Inc, Chicago, IL, USA). The
Kolmogorov–Smirnov test was used to test for normal distribution
of the data. Data are expressed as mean7s.d. or median
(interquartile range) as appropriate. Categorical variables are
presented as frequency counts, and intergroup comparisons were
analyzed by w2-test for smoking, sex, and medication with statins.
Statistical analysis of prevalence of diabetes was performed with
Fisher’s exact test. For continuous variables, the differences between
the groups were evaluated using unpaired Student’s t-test or
Mann–Whitney U test as appropriate. All of the comparisons of
compliance and PWV between the four groups were made in paired
age-matched samples as age is a major determinant of aortic
stiffness in both healthy and diseased populations.8,20,28–32 Pearson’s
correlation coefficients are given where indicated. Po0.05 (two
tailed) was considered significant and was corrected for multiple
comparisons using the Bonferroni method where appropriate.
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